Efectividad de la fibrina rica en leucocitos y plaquetas en el tratamiento de osteonecrosis mandibular relacionada con medicamentos: Una revisión sistemática

Autores/as

  • Rahul Mohandas Department of Oral and Maxillofacial Pathology and Oral Microbiology, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, India.
  • Subhashree Mohapatra Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, India.
  • Muskaan Singh Department of Oral and Maxillofacial Pathology and Oral Microbiology, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, India.
  • Supriya Kheur Department of Oral and Maxillofacial Pathology and Oral Microbiology, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, India.

DOI:

https://doi.org/10.17126/joralres.2024.015

Resumen

Introducción: La osteonecrosis mandibular relacionada con medicamentos (ONMRM) es un evento adverso raro pero significativo asociado principalmente con la ingesta de me-dicamentos antirresortivos y antiangiogénicos. Aunque las terapias antirresortivas y antiangiogénicas mejoran la esperanza de vida, particularmente en pacientes con cáncer, la ONMRM puede obstaculizar la calidad de vida del paciente debido a dolor, incomodidad, ansiedad, depresión, discapacidad del habla, dificultad para tragar y comer, evaluaciones y tratamientos médicos y dentales frecuentes, y la posibilidad de interrupción del tratamiento. La fibrina rica en plaquetas y leucocitos (L-PRF) es un agregado de plaquetas autólogo que promueve la curación de heridas al estimular la reepitelización, la angiogénesis y la producción de la matriz extracelular. Objetivo: La presente revisión sistemática tuvo como objetivo comparar los resultados en la literatura publicada sobre si L-PRF es un adyuvante efectivo y predecible al desbridamiento quirúrgico del hueso necrótico para mejorar la eficacia curativa en pacientes con ONMRM
Materiales y Métodos: Las bases de datos de PubMed, Scopus, Cochrane, ScienceDirect, LILACS y Web of Science se registraron utilizando los términos DeCS/MeSH predeterminados y los criterios de elegibilidad, y la búsqueda arrojó un total de cinco artículos. Dos estudios fueron retrospectivos, y tres estudios fueron series de casos.
Resultado: Diecisiete participantes recibieron una combi-nación de desbridamiento quirúrgico, membrana L-PRF y anti-bióticos. Se observó curación completa de heridas en el 70% de los participantes, y la mayoría de ellos se curaron sin ninguna complicación.
Conclusión: L-PRF como adyuvante para el desbridami-ento quirúrgico del hueso necrótico parece tener una asociación positiva con el resultado de curación en pacientes con ONMRM.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Cano-Durán JA, Peña-Cardelles JF, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017;9(8):e1051-e1059. doi: 10.4317/jced.54154. PMID: 28936298; PMCID: PMC5601107.

He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci. 2020;12(1):30. doi: 10.1038/s41368-020-00093-2. PMID: 33087699; PMCID: PMC7578793.

Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, McCloskey CA, Staffa JA, Willy M, Selby JV, Go AS; Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243-53. doi: 10.1016/j.joms.2009.03.050. Epub 2009 Sep 24. PMID: 19772941; PMCID: PMC10159647.

Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, McCloskey CA, Staffa JA, Willy M, Selby JV, Go AS; Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243-53. doi: 10.1016/j.joms.2009.03.050. Epub 2009 Sep 24. PMID: 19772941; PMCID: PMC10159647.

Tenore G, Mohsen A, Rossi AF, Palaia G, Rocchetti F, Cassoni A, Valentini V, Ottolenghi L, Polimeni A, Romeo U. Does Medication-Related Osteonecrosis of the Jaw Influence the Quality of Life of Cancer Patients? Biomedicines. 2020;8(4):95. doi: 10.3390/biomedicines8040095. PMID: 32344782; PMCID: PMC7235831.

On SW, Cho SW, Byun SH, Yang BE. Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches. Antioxidants (Basel). 2021;10(5):680. doi: 10.3390/antiox10050680. PMID: 33925361; PMCID: PMC8145192.

Dragonas P, Katsaros T, Avila-Ortiz G, Chambrone L, Schiavo JH, Palaiologou A. Effects of leukocyte-platelet-rich fibrin (L-PRF) in different intraoral bone grafting procedures: a systematic review. Int J Oral Maxillofac Surg. 2019;48(2):250-262. doi: 10.1016/j.ijom.2018.06.003. Epub 2018 Jul 7. PMID: 30058532.

Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(3):e37-44. doi: 10.1016/j.tripleo.2005.07.008. Epub 2006 Jan 19. PMID: 16504849.

Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun’s platelet-rich fibrin clot and membrane. J Periodontol. 2010;81(4):546-55. doi: 10.1902/jop.2009.090531. PMID: 20373539.

Saluja H, Dehane V, Mahindra U. Platelet-Rich fibrin: A second generation platelet concentrate and a new friend of oral and maxillofacial surgeons. Ann Maxillofac Surg. 2011;1(1):53-7. doi: 10.4103/2231-0746.83158. PMID: 23482459; PMCID: PMC3591032.

Tsirogianni AK, Moutsopoulos NM, Moutsopoulos HM. Wound healing: immunological aspects. Injury. 2006;37 Suppl 1:S5-12. doi: 10.1016/j.injury.2006.02.035. Epub 2006 Apr 17. PMID: 16616753.

Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016 ;20(9):2353-2360. doi: 10.1007/s00784-016-1719-1. Epub 2016 Jan 25. PMID: 26809431.

Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J. Platelet-Rich Fibrin and Soft Tissue Wound Healing: A Systematic Review. Tissue Eng Part B Rev. 2017;23(1):83-99. doi: 10.1089/ten.TEB.2016.0233. Epub 2016 Oct 10. PMID: 27672729.

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473. doi: 10.7326/M18-0850. Epub 2018 Sep 4. PMID: 30178033.

Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60-63. doi: 10.1136/bmjebm-2017-110853. Epub 2018 Feb 2. PMID: 29420178; PMCID: PMC6234235.

Bero L, Chartres N, Diong J, Fabbri A, Ghersi D, Lam J, Lau A, McDonald S, Mintzes B, Sutton P, Turton JL, Woodruff TJ. The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. Syst Rev. 2018;7(1):242. doi: 10.1186/s13643-018-0915-2. PMID: 30577874; PMCID: PMC6302384.

Agency for Healthcare Research and Quality (AHRQ).. Available from: https://www.ahrq.gov/

Maluf G, Caldas RJ, Silva Santos PS. Use of Leukocyte- and Platelet-Rich Fibrin in the Treatment of Medication-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2018; 76(1):88-96. doi: 10.1016/j.joms.2017.06.004. Epub 2017 Jun 12. PMID: 28675810.

Maluf G, Pinho MC, Cunha SR, Santos PS, Fregnani ER. Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report. Braz Dent J. 2016;27(3):353-8. doi: 10.1590/0103-6440201600662. PMID: 27224573.

Valente NA, Chatelain S, Alfonsi F, Mortellaro C, Barone A. Medication-Related Osteonecrosis of the Jaw: The Use of Leukocyte-Platelet-Rich Fibrin as an Adjunct in the Treatment. J Craniofac Surg. 2019;30(4):1095-1101. doi: 10.1097/SCS.0000000000005475. PMID: 30908443.

Özalp Ö, Y?ld?r?myan N, Öztürk C, Kocabalkan B, ?im?ek Kaya G, Sindel A, Altay MA. Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin. BMC Oral Health. 2021;21(1):613. doi: 10.1186/s12903-021-01965-7. PMID: 34852823; PMCID: PMC8638116.

Bouland C, Meuleman N, Widelec J, Keiani-Mothlagh K, Voisin C, Lagneaux L, Philippart P. Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF. J Stomatol Oral Maxillofac Surg. 2021;122(2):212-218. doi: 10.1016/j.jormas.2020.05.024. Epub 2020 Jun 12. PMID: 32540361.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.

Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol. 2012;48(5):469-74. doi: 10.1016/j.oraloncology.2011.12.004.

Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158-67. doi: 10.1016/j.tibtech.2008.11.009. Epub 2009 Jan 31. PMID: 19187989.

Dohan Ehrenfest DM, Pinto NR, Pereda A, Jiménez P, Corso MD, Kang BS, Nally M, Lanata N, Wang HL, Quirynen M. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane. Platelets. 2018;29(2):171-184. doi: 10.1080/09537104.2017.1293812. Epub 2017 Apr 24. PMID: 28437133.

Kang MH, Lee DK, Kim CW, Song IS, Jun SH. Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg. 2018 Oct;44(5):225-231. doi: 10.5125/jkaoms.2018.44.5.225. Epub 2018 Oct 26. Erratum in: J Korean Assoc Oral Maxillofac Surg. 2018;44(6):302. doi: 10.5125/jkaoms.2018.44.6.302. PMID: 30402414; PMCID: PMC6209697.

Chang HJ, Kim MJ, Ahn KM. Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases. Maxillofac Plast Reconstr Surg. 2023;45(1):12. doi: 10.1186/s40902-023-00377-7. PMID: 36853370; PMCID: PMC9975129.

Anastasilakis AD, Polyzos SA, Makras P. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179(1):R31-R45. doi: 10.1530/EJE-18-0056. Epub 2018 Apr 24. PMID: 29691303.

Wat WZM. Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw. Dent J (Basel). 2016;4(4):38. doi: 10.3390/dj4040038. PMID: 29563480; PMCID: PMC5806951.

Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45(7):551-4. doi: 10.1016/j.oraloncology.2009.01.002. Epub 2009 Feb 28. PMID: 19251474.

Ciobanu GA, Mogoant? L, Camen A, Ionescu M, Vlad D, Staicu IE, Munteanu CM, Gheorghi?? MI, Mercu? R, Sin EC, Popescu SM. Clinical and Histopathological Aspects of MRONJ in Cancer Patients. J Clin Med. 2023;12(10):3383. doi: 10.3390/jcm12103383. PMID: 37240491; PMCID: PMC10219482.

Sacco R, Woolley J, Yates J, Calasans-Maia MD, Akintola O, Patel V. The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review. J Res Med Sci. 2021;26:23. doi: 10.4103/jrms.JRMS_794_20. PMID: 34221052; PMCID: PMC8240545.

Park JH, Kim JW, Kim SJ. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? J Oral Maxillofac Surg. 2017;75(6):1176-1184. doi: 10.1016/j.joms.2016.12.005. Epub 2016 Dec 11. PMID: 28042979.

Publicado

2024-03-31

Cómo citar

1.
Mohandas R, Mohapatra S, Singh M, Kheur S. Efectividad de la fibrina rica en leucocitos y plaquetas en el tratamiento de osteonecrosis mandibular relacionada con medicamentos: Una revisión sistemática. J Oral Res [Internet]. 31 de marzo de 2024 [citado 22 de enero de 2025];13:170-82. Disponible en: https://revistas.udec.cl/index.php/journal_of_oral_research/article/view/18415

Número

Vol. 13 (2024)

Sección

Review
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Este es una Revista de acceso abierto distribuido bajo los términos de Creative Commons Attribution License (CC BY 4.0). Se permite el uso, distribución o reproducción en otros foros, siempre que se acredite al autor o autores originales y a los propietarios de los derechos de autor y se cite la publicación original en esta revista, de acuerdo con la práctica académica aceptada. No se permite ningún uso, distribución o reproducción que no cumpla con estos términos. © 2023.